Clinical Trials Browser

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT05477264 2024-04-03

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

Phase 2 Recruiting

38 enrolled

Lymphoid

Lymphoma

NCT05627115 2023-11-29

RATiFY

Phase 2 Not yet recruiting

80 enrolled

Lymphoid

Hodgkin Disease

NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Phase 1/2 Unknown

309 enrolled

LymphoidOther solid neoplasm

Solid Tumor

NCT05659628 2022-12-21

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Phase 1 Recruiting

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase 1 Completed

75 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Phase 2 Unknown

54 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04899414 2021-05-24

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

Phase 2 Unknown

50 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04843267 2021-04-13

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Phase 2 Unknown

30 enrolled

Lymphoid

Hodgkin Disease

Clinical Trials

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

EpiRev-NKT

HOVON164HL

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

TOUCH

FIL_Tisle-HL

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

RATiFY

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT